Devine, M. J., Kaganovich, A., Ryten, M., Mamais, A., Trabzuni, D., Manzoni, C., McGoldrick, P., Chan, D., Dillman, A., Zerle, J., Horan, S., Taanman, J.-W., Hardy, J., Marti-Masso, J.-F., Healy, D., Schapira, A. H., Wolozin, B., Bandopadhyay, R., Cookson, M. R., van der Brug, M. P. and Lewis, P. A.
Pathogenic LRRK2 mutations do not alter gene expression in cell model systems or human brain tissue.
PLoS ONE, 6 (7).
To link to this article DOI: 10.1371/journal.pone.0022489
Point mutations in LRRK2 cause autosomal dominant Parkinson's disease. Despite extensive efforts to determine the mechanism of cell death in patients with LRRK2 mutations, the aetiology of LRRK2 PD is not well understood. To examine possible alterations in gene expression linked to the presence of LRRK2 mutations, we carried out a case versus control analysis of global gene expression in three systems: fibroblasts isolated from LRRK2 mutation carriers and healthy, non-mutation carrying controls; brain tissue from G2019S mutation carriers and controls; and HEK293 inducible LRRK2 wild type and mutant cell lines. No significant alteration in gene expression was found in these systems following correction for multiple testing. These data suggest that any alterations in basal gene expression in fibroblasts or cell lines containing mutations in LRRK2 are likely to be quantitatively small. This work suggests that LRRK2 is unlikely to play a direct role in modulation of gene expression, although it remains possible that this protein can influence mRNA expression under pathogenic cicumstances.
|Parkinsonﾒs Disease Society|
|Date Deposited:||17 Oct 2012 10:20|
|Last Modified:||26 Jun 2014 19:49|
Download Statistics for this item.
University Staff: Request a correction | Centaur Editors: Update this record